Immunotherapy as a strategy for treatment of leishmaniasis: A review of the literature

Immunotherapy

Volumn 1, Issue 5, 2009, Pages 765-776

  Okwor, Ifeoma ^b   Uzonna, Jude E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE

Author keywords

Chemotherapy; Immunology; Immunotherapy; Leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B ARABINOLACTAM; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; BCG VACCINE; DNA VACCINE; INTERLEUKIN 10 RECEPTOR MONOCLONAL ANTIBODY; INTERLEUKIN 4 ANTIBODY; LEISHMANIA VACCINE; LEISHMUNE; MEGLUMINE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; MONOCLONAL ANTIBODY; PAROMOMYCIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; LEISHMANIASIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, PROTOZOAN; CYTOKINES; DRUG COSTS; HUMANS; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; TH1-TH2 BALANCE; VACCINES, DNA;

EID: 77953433941     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.40     Document Type: Review

References (127)

1. Oldham RK: Principles of Cancer Biotherapy. Kluwer Academic Publishers, Dordrecht, Netherlands, (2006).
2. Oldham RK, Smalley RV: Immunotherapy: The old and the new. J. Biol. Response Mod. 2, 1-37 (1983).
3. Desjeux P: Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
4. Desjeux P: Human leishmaniases: epidemiology and public health aspects. World Health Stat. Q. 45, 267-275 (1992).
5. Desjeux P: Leishmaniasis. Nat. Rev. Microbiol. 2, 692 (2004).
6. Berman J: Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16, 397-401 (2003).
7. Bailey MS, Lockwood DN: Cutaneous leishmaniasis. Clin. Dermatol. 25, 203-211 (2007). •• Excellent review of diagnosis, treatment and prevention of cutaneous leishmaniasis.
8. Gonzalez U, Pinart M, Reveiz L, Alvar J: Interventions for old world cutaneous leishmaniasis. Cochrane Database Syst. Rev. 4, CD005067 (2008).
9. Murray HW, Berman JD, Davies CR, Saravia NG: Advances in leishmaniasis. Lancet 366, 1561-1577 (2005). •• Interesting and exhaustive review on clinical features and treatment of both cutaneous and visceral leishmaniasis.
10. Olliaro PL, Guerin PJ, Gerstl S et al.: Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5, 763-774 (2005).
11. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK: Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581 (2007). (Pubitemid 46961002)
12. Sundar S, Jha TK, Thakur CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347, 1739-1746 (2002). (Pubitemid 35375612)
13. Sundar S, Rai M, Chakravarty J et al.: New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis. 47, 1000-1006 (2008).
14. Koenecke C, Ukena SN, Ganser A, Franzke A: Regulatory T cells as therapeutic target in hodgkin's lymphoma. Expert Opin. Ther. Targets 12, 769-782 (2008). (Pubitemid 351877305)
15. Weiner GJ: CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv. Drug Deliv. Rev. 61, 263-267 (2009).
16. Fujii S, Goto A, Shimizu K: Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 113, 4262-4272 (2009).
17. Niederberger V: Allergen-specific immunotherapy. Immunol. Lett. 122, 131-133 (2009).
18. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS: Open-label trial of therapeutic immunization with oral V-5 immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 26, 2733-2737 (2008).
19. Alexander J, Russell DG: The interaction of Leishmania species with macrophages. Adv. Parasitol. 31, 175-254 (1992).
20. Peters NC, Egen JG, Secundino N et al.: In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321, 970-974 (2008).
21. Woelbing F, Kostka SL, Moelle K et al.: Uptake of Leishmania major by dendritic cells is mediated by Fc-γ receptors and facilitates acquisition of protective immunity. J. Exp. Med. 203, 177-188 (2006). (Pubitemid 43139656)
22. Laufs H, Muller K, Fleischer J et al.: Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect. Immun. 70, 826-835 (2002). (Pubitemid 34083846)
23. Aga E, Katschinski DM, van Zandbergen G et al.: Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J. Immunol. 169, 898-905 (2002). (Pubitemid 34753446)
24. van Zandbergen G, Klinger M, Mueller A et al.: Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol. 173, 6521-6525 (2004). (Pubitemid 39541033)
25. John B, Hunter CA: Immunology. Neutrophil soldiers or trojan horses? Science 321, 917-918 (2008).
26. Moser M, Murphy KM: Dendritic cell regulation of Th1-Th2 development. Nat. Immunol. 1, 199-205 (2000).
27. Afonso LC, Scharton TM, Vieira LQ et al.: The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237 (1994).
28. Park AY, Hondowicz BD, Scott P: IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165, 896-902 (2000).
29. Park AY, Hondowicz B, Kopf M, Scott P: The role of IL-12 in maintaining resistance to Leishmania major. J. Immunol. 168, 5771-5777 (2002). (Pubitemid 34556162)
30. + T cells resulting in a state of unresponsiveness to IL-12. J. Immunol 161, 6156-6163 (1998). (Pubitemid 28535988)
31. + Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Adv. Exp. Med. Biol. 452, 53-60 (1998). (Pubitemid 28478084)
32. Louis J, Himmelrich H, Parra-Lopez C, Tacchini-Cottier F, Launois P: Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10, 459-464 (1998). (Pubitemid 28393830)
33. + T-cell subsets in the regulation of parasite immunity and disease. Immunol. Rev. 112, 161-182 (1989). (Pubitemid 20048812)
34. Scott P: The role of Th1 and Th2 cells in experimental cutaneous leishmaniasis. Exp. Parasitol. 68, 369-372 (1989).
35. Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13, 151-177 (1995). •• Highly exhaustive and informative review providing a good basic understanding of the immunology of cutaneous leishmaniasis.
36. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P: IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154, 5320-5330 (1995).
37. Afonso LC, Scott P: Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61, 2952-2959 (1993).
38. Himmelrich H, Launois P, Maillard I et al.: In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164, 4819-4825 (2000). (Pubitemid 30238085)
39. Kane MM, Mosser DM: The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166, 1141-1147 (2001).
40. Groux H, Cottrez F, Rouleau M et al.: A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol. 162, 1723-1729 (1999). (Pubitemid 29307051)
41. Chatelain R, Mauze S, Coffman RL: Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 21, 211-218 (1999). (Pubitemid 29158767)
42. Mosmann TR, Moore KW: The role of IL-10 in crossregulation of Th1 and Th2 responses. Immunol. Today 12, A49-A53 (1991).
43. Fiorentino DF, Zlotnik A, Vieira P et al.: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444-3451 (1991).
44. Allenbach C, Launois P, Mueller C, Tacchini-Cottier F: An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection. Eur. J. Immunol. 38, 720-731 (2008).
45. Li J, Hunter CA, Farrell JP: Anti-TGF-β treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. 162, 974-979 (1999). (Pubitemid 29035423)
46. Padigel UM, Farrell JP: Control of infection with Leishmania major in susceptible BALB/c mice lacking the common γ-chain for FcR is associated with reduced production of IL-10 and TGF-β by parasitized cells. J. Immunol. 174, 6340-6345 (2005).
47. Xu G, Liu D, Fan Y et al.: Lymphotoxin αβ 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J. Immunol. 179, 5358-5366 (2007).
48. + Th1 cell response, and resistance to Leishmania major. J. Immunol. 179, 6901-6909 (2007).
49. Engwerda CR, Kaye PM: Organ-specific immune responses associated with infectious disease. Immunol. Today 21, 73-78 (2000). •• Excellent review on the important/problematic issue of organ-specific immune responses in visceral leishmaniasis.
50. McElrath MJ, Murray HW, Cohn ZA: The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 167, 1927-1937 (1988).
51. Alexander CE, Kaye PM, Engwerda CR: CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur. J. Immunol. 31, 1199-1210 (2001).
52. Liew FY, O'Donnell CA: Immunology of leishmaniasis. Adv. Parasitol. 32, 161-259 (1993).
53. Cotterell SE, Engwerda CR, Kaye PM: Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur. J. Immunol. 29, 203-214 (1999).
54. Kaye PM, Svensson M, Ato M et al.: The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201, 239-253 (2004).
55. Stanley AC, Engwerda CR: Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85, 138-147 (2007).
56. Rodrigues OR, Marques C, Soares-Clemente M, Ferronha MH, Santos-Gomes GM: Identification of regulatory T cells during experimental Leishmania infantum infection. Immunobiology 214, 101-111 (2009).
57. Smelt SC, Engwerda CR, McCrossen M, Kaye PM: Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J. Immunol. 158, 3813-3821 (1997). (Pubitemid 127488739)
58. Engwerda CR, Ato M, Cotterell SE et al.: A role for tumor necrosis factor-α in remodeling the splenic marginal zone during Leishmania donovani infection. Am. J. Pathol. 161, 429-437 (2002). (Pubitemid 36142152)
59. Tripathi P, Singh V, Naik S: Immune response to Leishmania: paradox rather than paradigm. FEMS Immunol. Med. Microbiol. 51, 229-242 (2007). (Pubitemid 47547509)
60. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A: Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 68, 1760-1764 (2000). (Pubitemid 30164796)
61. + T cells without affecting cellular immune responses. Microbiol. Immunol. 51, 1003-1011 (2007). (Pubitemid 47623414)
62. Bottrel RL, Dutra WO, Martins FA et al.: Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect. Immun. 69, 3232-3239 (2001).
63. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM: Cytokine profile and pathology in human leishmaniasis. Braz. J. Med. Biol. Res. 31, 143-148 (1998). (Pubitemid 128524624)
64. Follador I, Araujo C, Bacellar O et al.: Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin. Infect. Dis. 34, E54-E58 (2002).
65. Solomon M, Baum S, Barzilai A et al.: Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J. Eur. Acad. Dermatol. Venereol. DOI: 10.1111/j.1468-3083.2009.03157.x (2009) (Epub ahead of print).
66. Sundar S, Mehta H, Suresh AV et al.: Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis. 38, 377-383 (2004). (Pubitemid 38200114)
67. Munir A, Janjua SA, Hussain I: Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of Old World cutaneous leishmaniasis. Acta Dermatovenerol. Croat. 16, 60-64 (2008). (Pubitemid 351879797)
68. Arana BA, Mendoza CE, Rizzo NR, Kroeger A: Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. 65, 466-470 (2001).
69. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R: Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91, 153-160 (2004). (Pubitemid 38952716)
70. Faghihi G, Tavakoli-kia R: Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin. Exp. Dermatol. 28, 13-16 (2003). (Pubitemid 36197553)
71. Iraji F, Sadeghinia A: Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann. Trop. Med. Parasitol. 99, 3-9 (2005).
72. Berman JD: Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10, 560-586 (1988).
73. Berman JD: Primary agent for leishmaniasis. Am. J. Trop. Med. Hyg. 38, 652 (1988).
74. Herwaldt BL, Berman JD: Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46, 296-306 (1992).
75. Croft SL, Sundar S, Fairlamb AH: Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111-126 (2006). •• Interesting review that takes an in-depth look at host and parasite factors that drive the development of drug resistance in leishmaniasis.
76. Murray HW: Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev. Anti Infect. Ther. 2, 279-292 (2004).
77. Santos DO, Coutinho CE, Madeira MF et al.: leishmaniasis treatment - a challenge that remains: a review. Parasitol. Res. 103, 1-10 (2008).
78. Sundar S, Mehta H, Chhabra A et al.: Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis. 42, 608-613 (2006). (Pubitemid 43271372)
79. Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ: Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43, 2209-2214 (1999). (Pubitemid 29421202)
80. Palumbo E: Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. Braz. J. Infect. Dis. 12, 2-4 (2008).
81. Singh UK, Prasad R, Mishra OP, Jayswal BP: Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J. Pediatr. 73, 1077-1080 (2006).
82. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M: Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl. 1), S26-S33 (2006). (Pubitemid 44490165)
83. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K: Relapse of visceral leishmaniasis after miltefosine treatment in a nepalese patient. Am. J. Trop. Med. Hyg. 80, 580-582 (2009).
84. Murray HW, Delph-Etienne S: Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181, 795-799 (2000).
85. Bailey MS, Lockwood DN: Cutaneous leishmaniasis. Clin. Dermatol. 25, 203-211 (2007).
86. Genaro O, de Toledo VP, da Costa CA et al.: Vaccine for prophylaxis and immunotherapy, Brazil. Clin. Dermatol. 14, 503-512 (1996).
87. Ghalib H, Modabber F: Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol. Dis. 6, 7 (2007). (Pubitemid 47543166)
88. Mayrink W, Magalhaes PA, Michalick MS et al.: Immunotherapy as a treatment of american cutaneous leishmaniasis: preliminary studies in Brazil. Parassitologia 34, 159-165 (1992).
89. Convit J, Castellanos PL, Rondon A et al.: Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1, 401-405 (1987). (Pubitemid 17016578)
90. Convit J, Castellanos PL, Ulrich M et al.: Immunotherapy of localized, intermediate, and diffuse forms of american cutaneous leishmaniasis. J. Infect. Dis. 160, 104-115 (1989). (Pubitemid 19162999)
91. Convit J, Ulrich M, Zerpa O et al.: Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans. R Soc. Trop. Med. Hyg. 97, 469-472 (2003).
92. Convit J, Ulrich M, Polegre MA et al.: Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem. Inst. Oswaldo Cruz 99, 57-62 (2004). (Pubitemid 38406266)
93. Mayrink W, Botelho AC, Magalhaes PA et al.: Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev. Soc. Bras. Med. Trop. 39, 14-21 (2006). •• Excellent article on status of immunotherapy in South America, particularly in Brazil. (Pubitemid 43305007)
94. Musa AM, Khalil EA, Mahgoub FA et al.: Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 102, 58-63 (2008).
95. Gurunathan S, Klinman DM, Seder RA: DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974 (2000). (Pubitemid 30365401)
96. Bhowmick S, Ali N: Recent developments in leishmaniasis vaccine delivery systems. Expert Opin. Drug Deliv. 5, 789-803 (2008). •• Recent article containing comprehensive information about vaccine development as well as the advantages and disadvantages of different vaccine-delivery strategies.
97. Robinson HL, Pertmer TM: DNA vaccines for viral infections: basic studies and applications. Adv. Virus Res. 55, 1-74 (2000).
98. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158, 4591-4601 (1997). (Pubitemid 127483777)
99. Geissler M, Gesien A, Tokushige K, Wands JR: Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 158, 1231-1237 (1997). (Pubitemid 127469946)
100. Xu D, Liew FY: Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84, 173-176 (1995).
101. Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C: DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Vaccine 27, 99-106 (2008).
102. Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjolander A: Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 18, 3011-3017 (2000). (Pubitemid 30303805)
103. Gamboa-Leon R, Paraguai de Souza E, Borja-Cabrera GP et al.: Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 24, 4863-4873 (2006). (Pubitemid 44218848)
104. Santos WR, Aguiar IA, Paraguai de Souza E et al.: Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21, 4668-4676 (2003).
105. Santos FN, Borja-Cabrera GP, Miyashiro LM et al.: Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 25, 6176-6190 (2007).
106. Badaro R, Lobo I, Nakatani M et al.: Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz. J. Infect. Dis. 5, 223-232 (2001).
107. Webb JR, Campos-Neto A, Ovendale PJ et al.: Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66, 3279-3289 (1998). (Pubitemid 28303127)
108. Webb JR, Kaufmann D, Campos-Neto A, Reed SG: Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157, 5034-5041 (1996). (Pubitemid 126449584)
109. Skeiky YA, Guderian JA, Benson DR et al.: A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181, 1527-1537 (1995).
110. Skeiky YA, Benson DR, Guderian JA et al.: Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect. Immun. 63, 4105-4114 (1995).
111. Badaro R, Lobo I, Munos A et al.: Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194, 1151-1159 (2006).
112. Barroso PA, Marco JD, CalvopinaM et al.: A trial of immunotherapy against Leishmanm amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from mycobacterium tuberculosis, alone or combined with meglumine antimoniate. J. Antimicrob. Chemother. 59, 1123-1129 (2007).
113. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002). (Pubitemid 35477041)
114. + regulatory T cells in Leishmania infection. Expert Opin. Biol. Ther. 3, 875-885 (2003).
115. Uzonna JE, Bretscher PA: Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur. J. Immunol. 31, 3175-3184 (2001).
116. Sadick MD, Heinzel FP, Holaday BJ et al.: Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody, evidence for a T cell-dependent, interferon γ-independent mechanism. J. Exp. Med. 171, 115-127 (1990).
117. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK: Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177, 1505-1509 (1993).
118. Nabors GS, Farrell JP: Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect. Immun. 62, 5498-5504 (1994).
119. Gicheru MM, Olobo JO, Anjili CO et al.: Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69, 245-251 (2001).
120. Murray HW, Moreira AL, Lu CM et al.: Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188, 458-464 (2003).
121. Murray HW: Interleukin 10 receptor blockade - pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop. 93, 295-301 (2005).
122. Bodas M, Jain N, Awasthi A et al.: Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy. J. Immunol. 177, 4636-4643 (2006). (Pubitemid 44469796)
123. Murray HW: Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45, 2185-2197 (2001).
124. Cruz I, Nieto J, Moreno J et al.: Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 123, 357-388 (2006).
125. Harms G, Chehade AK, Douba M et al.: A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-γ in the local treatment of cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 85, 214-216 (1991).
126. Murray HW: Treatment of visceral leishmaniasis in 2004. Am. J. Trop. Med. Hyg. 71, 787-794 (2004).
127. Li J, Sutterwala S, Farrell JP: Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and γ interferon depends on continued interleukin-12 production. Infect. Immun. 65, 3225-3230 (1997). (Pubitemid 27342403)